A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

Exclusion Criteria

• •1. Unable to understand information about the study or are expected not to collaborate with the study team.
• •2. Concurrent serious disease, other than ALS, at the discretion of the nvestigator.
• •3. Pregnancy.
• •4. Patients of childbearing potential not willing to use adequate double contraception with less than 1 percentage failure rate after the screening visit until the last visit.
• •5. Addiction to drugs or alcohol.
• •6. Confirmed HIV, hepatitis B or hepatitis C.
• •7. Known bleeding disorders or abnormal bleeding events.
• •8. Treatment with anticoagulant drugs warfarin and novel oral anticoagulants (NOAC) within the last 14 days prior to screening.
• •9. Treatment with Riluzole or Lamotrigine within the last 28 days prior to study drug administration.
• •10. Hypersensitivity to dextran sulfate.
• •11. Poor venous access.
• •12. Patients with clinically significant abnormal PK-INR, fibrinogen, von Willebrand factor and activated partial thromboplastin time (APTT) at screening.